Issue #10
Greetings dear reader. This week splits into capital conviction and capital risk: the Moopen family bought back ₹350 Cr of Aster DM stock from an exiting PE investor, and Max Healthcare’s Abhay Soi laid out the phasing behind its 10,000-bed build — occupancy first, EBITDA chases — while the Delhi High Court ordered a forensic audit of decade-old Fortis-IHH-RHT transactions, a reminder that promoter-era liabilities can resurface long after a chain changes hands. On the Builder side, MedGenome’s move into personalised relapse monitoring and a new Bain-HealthQuad report both point to the same constraint: the AI and diagnostics opportunity is real, but gated by data foundations most providers haven’t built yet — exactly the thread running through this week’s A|P pieces.
Have a great week ahead — Aviral
In the news
MedGenome launches personalised blood test to detect and monitor cancer relapse
- Genomics diagnostics firm MedGenome launched OncoTrack MRD, a personalised, tumour-informed blood test for patients previously diagnosed with cancer. The test is built using each patient’s own tumour tissue and analyses circulating tumour DNA (ctDNA) to detect and measure residual disease, flag potential recurrence earlier than conventional methods, and support treatment decisions.
- Why it matters: This is a Builder-side example of a diagnostics company moving from population-level genomic testing into a personalised, longitudinal monitoring product — the tumour-informed design built from each patient’s own tissue is what differentiates it from cheaper generic ctDNA panels, and is the harder, more defensible product to build.
- Takeaway: For a Builder in diagnostics or oncology-adjacent health tech, MedGenome’s move is worth studying as a positioning lesson — a personalised, tumour-informed product commands a different value conversation and price point with oncologists than a one-size-fits-all screening test, even where the underlying ctDNA technology is similar.
Aster DM Quality Care’s promoter bumps up stake with ₹350 cr share purchase
- Union (Mauritius) Holdings Ltd, owned by Dr. Azad Moopen and family, acquired 46.09 lakh equity shares (~0.57% of paid-up equity) of Aster DM Quality Care from TPG-backed Centella Mauritius Holdings for approximately ₹350.34 crore (₹760/share, acquired September 2, 2026) — taking the Moopen family’s stake to approximately 24.58%. The company said the purchase reflects the promoter family’s confidence in the platform’s ability to deliver sustainable long-term value.
- Why it matters: A promoter buying back stock at scale from a departing PE investor is an unambiguous signal — it’s the founder putting new capital in, timed exactly as a financial sponsor trims its position, which reads differently than a routine market purchase or a press statement.
- Takeaway: If your hospital’s capital structure includes external investors, a deliberate, disclosed founder buy-back at the moment a sponsor exits is a stronger public confidence signal worth planning for than reactive messaging after the fact.
Metropolis Healthcare to expand presence to 1,000 towns in 3 years from 750 currently
- Diagnostic chain Metropolis Healthcare said it aims to expand its geographical footprint to 1,000 towns across India within three years, up from 750 currently, as part of an “acceleration” phase. It plans to improve infrastructure efficiency by increasing its centre-to-lab ratio from 24 collection centres per laboratory to 35 over the next two to three years. Executive Chairperson Ameera Shah noted the Indian diagnostics industry is valued at roughly $11 billion, growing at 11%, with 85% of the sector still unorganised.
- Why it matters: Metropolis is deliberately loosening its centre-to-lab ratio — betting that fewer, more efficient labs can service more collection points through better logistics, rather than building a lab in every town, a capital-efficiency lever most smaller diagnostic operators don’t optimise for.
- Takeaway: If you run or are building a diagnostics network, benchmark your own centre-to-lab ratio against Metropolis’s 35:1 target — a materially lower ratio may mean you’re over-investing in lab infrastructure relative to what your collection network actually needs.
AI in healthcare: Remote monitoring, ICU optimisation to be next growth frontiers, says report
- A joint report by Bain & Company and HealthQuad, ‘AI in Indian Healthcare Delivery’, found Indian healthcare providers are shifting AI from experimental testing to real-world use, with remote patient monitoring, OT/ICU optimisation and post-discharge chronic disease management identified as the next major growth frontiers. Providers are also deploying AI to reduce administrative burden on clinicians. The report flagged connected clinical care as a significant forward opportunity currently constrained by a 35% EMR adoption rate, and warned that as hospitals build the necessary data foundations, the gap between early movers and the rest of the industry will widen quickly.
- Why it matters: The report’s core warning is about timing risk — once hospitals with mature EMR and data foundations pull ahead on AI-driven clinical care, catching up requires years of data infrastructure work already done by competitors, not just deploying an AI tool.
- Takeaway: If your hospital’s EMR adoption or data structuring is still immature, treat that as the actual bottleneck to future AI capability — the AI tools themselves are increasingly commoditised, but whether your own clinical data is usable by them is not.
Park Medi World incorporates subsidiary to set up 550-bed hospital in Prayagraj
- Park Medi World incorporated a wholly-owned subsidiary, Park Medicity Prayagraj Ltd, to develop and operate a 550-bed multi-super-speciality hospital in Uttar Pradesh, under a Public-Private Partnership (PPP) project awarded by the Prayagraj Municipal Corporation. The subsidiary was incorporated with Park Medi World subscribing to 1,50,000 equity shares at ₹10 face value (₹15 lakh total).
- Why it matters: This is a concrete instance of Park Medi World’s broader north-India expansion (1,450 beds targeted by FY28) and is structured as a PPP with municipal backing rather than a pure private greenfield build — a different capital outlay and approval dynamic than the company’s other expansion moves.
- Takeaway: If a PPP opportunity with a municipal or state body comes up in your market, this is worth studying as a structure — a dedicated project subsidiary, rather than running the project through the parent entity, ring-fences the PPP project’s risk and can simplify compliance with the partnership’s specific terms.
Delhi HC orders forensic audit of Fortis, IHH and RHT transactions in $4.6-billion Daiichi-Singh case
- The Delhi High Court ordered the appointment of a forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’s IHH Healthcare and Singapore’s RHT Health Trust, in a case linked to the $4.6 billion arbitration award Daiichi Sankyo won against Malvinder and Shivinder Singh in 2008. Daiichi sought the forensic auditor to investigate the transactions and any nexus between RHT, former FHL promoters and others, following Supreme Court directions issued September 22, 2022.
- Why it matters: This reopens scrutiny of a Tier-1 chain’s ownership history years after the original scandal and long after the chain changed hands (Fortis is now under IHH/Manipal control) — promoter-era liabilities and related-party transaction structures can resurface well after an acquisition closes.
- Takeaway: If M&A or external investment is on your horizon as an exit or growth path, treat this as a live case study in why acquirers increasingly demand extended reps-and-warranties and forensic due diligence on promoter-era transactions, not just current-year financials.
‘First You Want to See Occupancy Move Up, EBITDA Will Chase’: Soi on Max Healthcare’s 10,000-Bed Expansion
- Max Healthcare Chairman & MD Abhay Soi laid out the operating trajectory behind its 10,000-bed expansion across brownfield projects, new hospitals and acquisitions: occupancy rises first, revenue follows, EBITDA chases last. The Saket brownfield addition (400 new beds, ~1,200 total, now Delhi’s largest private hospital by capacity) illustrates the phasing — beds are opened in tranches because the cost base is incurred upfront while revenue and EBITDA ramp only as occupancy builds; each successive tranche of beds contributes more EBITDA since prior costs are already sunk. Expansion and acquisition decisions are gated by scale and ROCE (a 20% ROCE target over four years) — Max won’t chase a small, high-return facility that can’t scale further. Soi frames the long-term case around India’s ageing demographic (average age 29, projected to reach 43 within 14-15 years) and notes the sector’s thin 8-9% net margins mean nearly all returns get redeployed into the next wave of capacity (3,500 → 6,000 → a targeted 10,200 beds).
- Why it matters: This is a specific, numbers-backed operating playbook for brownfield hospital expansion — flat-to-negative EBITDA in the first 1-2 quarters after opening new capacity, accelerating only once occupancy clears roughly 50%, is the pattern to model for rather than assuming EBITDA scales linearly with beds added.
- Takeaway: If you’re planning a bed expansion, build your financial model around Soi’s phasing logic — budget cash runway for a multi-quarter lag between opening capacity and seeing EBITDA contribution, and evaluate any new facility on its ability to scale further, not just its standalone return.
Popular on A|P this week
Insights to help you grow and optimise your healthcare business.
NABH Digital Health Standard for Hospital’s IMS Chapter Explained: Information Management System Requirements
- IMS is where every other chapter’s data becomes trustworthy or doesn’t — AAC’s admission records, COP’s care plans, MOM’s medication logs, DOM’s operational data, FPM’s billing records, and HRM’s staff records are all only as reliable as the data standards and governance IMS requires underneath them. A hospital can pass Silver and Gold with fragmented, non-interoperable data; IMS is where that stops being acceptable for Platinum.
- Takeaway: Answer the four ownership questions from the piece with named people, not departments — who owns data format decisions, who’s accountable for privacy mishandling, who approves and revisits the IT budget, and who’s the point of contact when an outside institution wants to interface with your HIMS. “No one specifically” to more than one is the actual gap, not a missing piece of software.
NABH Digital Health Standard for Hospital’s HRM Chapter Explained: Digital Human Resource Management
- A hospital chasing Silver tier can legitimately defer HRM almost entirely, but that’s sequencing, not skipping — digital goal-setting, performance evaluation, ABDM-linked credentialing, and self-service HR are all Excellence-band, so a hospital with Gold or Platinum ambitions will eventually need to build essentially all of it.
- Takeaway: Run the two-column self-check from the piece — for staff records, rostering, offboarding notifications, performance evaluation, and training history, mark what’s already digital versus still manual — and treat the “still manual” column as fair to defer only if Silver is the actual ceiling, not the current excuse.
The Six Decisions of Hospital Marketing Strategy in India
- Most hospitals whose marketing “isn’t working” have actually skipped straight to channel and budget decisions (four and five) without resolving position, trust, or the rented-vs-compounding diagnostic first — which is why a bigger ad spend just produces a bigger, equally temporary spike.
- Takeaway: Run the six-question self-check at the end of the piece in order: complete “this is the hospital for people who need ___,” rate the last/first ten minutes of a patient visit, pull last quarter’s repeat-visit rate and referral share, and check whether current channel spend and empanelment actually match the answer to question one. Fix the first gap you hit before touching the next decision.
You are receiving this newsletter because you are on the mailing list of Aviral Prakash. If you would like to unsubscribe / update your e-mail address or provide feedback on how this newsletter can be made better please write to info@aviralprakash.com
Copyright ©️ 2026 | Aviral Prakash